老化产药:增强衰老向干预的有希望的方法
Mengyang Chang1, Yue Dong2, Alexis B Cruickshank-Taylor2
1Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona, 85721, USA.
Chembiochem : a European journal of chemical biology
|July 26, 2024
概括
老化前药物通过利用银河糖来选择性地消除衰老细胞,以激活药物,以应对与衰老相关的β-银河糖酶 (SA-β-gal). 这种方法旨在最大限度地减少副作用,并提前治疗衰老.
科学领域:
- 生物医学科学 生物医学科学
- 老年学是一门学科.
- 药物开发 药物开发
背景情况:
- 细胞衰老是衰老和与年龄有关的疾病的治疗点.
- 老化剂显示出有前途,但有副作用限制了临床使用.
- 需要对衰老细胞 (SnCs) 进行选择性切除.
研究的目的:
- 审查用于选择性SnC切除的老化前药物设计.
- 根据激活机制对前药物进行分类.
- 为了突出 senolytic 前药开发的进步.
主要方法:
- 预制药的分类为银河糖修饰和生物对等激活等级.
- 描述银河糖部分结合和自我焚烧链接器.
- 解释使用二二氨酸用于SA-β-gal传感的生物对等前期药物.
主要成果:
- 老化前期药物被设计为通过老化相关的β-galactosidase (SA-β-gal) 激活.
- 确定了两个主要类型的前药物:银河糖修饰和生物对等.
- 像PROTACs和光动力疗法这样的新老化药物被纳入前期药物设计中.
结论:
- 老龄化前期药物为克服当前老龄化药物的副作用提供了一个有希望的策略.
- 产前药物设计可实现有针对性的输送和激活,增强治疗潜力.
- 这些进展有望促进老化疗法的临床转化.
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


